FDMT
4D Molecular Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+4/100
Last price
12.50
▼ 0.42 (3.25%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
13.10
Prev close
12.92
Day high
13.02
Day low
12.30
Volume
1.17M
Market cap
$693.87M
P/E (TTM)
—
52W range
6.96 – 16.93
Day trading desk
Gap from prior close
+1.39%
Prior close 12.92
VWAP
12.58
-0.60% from price
Relative volume
2.12×
Unusually busy
Session range
13.91%
11.50 – 13.10
Position in range
63%
Mid range
ATR (14D)
0.98
7.85% of price
Prior day high
13.86
PDH
Prior day low
12.61
PDL
Bid / ask spread
—
Quote not published
Session volume
1.95M
Avg 920.14K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-13.32%
-15.3%
1M
-16.10%
-17.3%
3M
-3.53%
-8.1%
6M
+22.66%
+4.5%
YTD
+67.47%
+53.2%
1Y
+46.90%
+30.5%
3Y
-1.34%
-83.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on FDMT open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-291.67K
Net selling
Buy transactions
6
71.86K shares
Sell transactions
12
363.53K shares
Net transactions
+18
Buys less sells
Sell : buy shares
5.1 : 1
Heavily one-sided
Insider-held shares
1.62M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 16, 26 | BIZILY SCOTT Officer |
SELL | 1.64K | $22.32K | Direct |
| Sep 16, 26 | BIZILY SCOTT Officer |
CONVERSION | 1.64K | $6.77K | Direct |
| Sep 14, 26 | KIRN DAVID Chief Executive Officer |
SELL | 58.33K | $811.00K | Direct |
| Sep 1, 26 | BIZILY SCOTT Officer |
SELL | 584 | $8.18K | Direct |
| Sep 1, 26 | BIZILY SCOTT Officer |
CONVERSION | 584 | $3.79K | Direct |
| Aug 19, 26 | KIRN DAVID Chief Executive Officer |
SELL | 69.08K | $1.09M | Direct |
| Aug 19, 26 | KIRN DAVID Chief Executive Officer |
CONVERSION | 50.00K | $207.00K | Direct |
| Aug 17, 26 | BIZILY SCOTT Officer |
SELL | 3.27K | $39.57K | Direct |
| Aug 17, 26 | BIZILY SCOTT Officer |
CONVERSION | 3.27K | $13.54K | Direct |
| Aug 4, 26 | KIRN DAVID Chief Executive Officer |
SELL | 26.84K | $274.60K | Direct |
| Aug 3, 26 | KIRN DAVID Chief Executive Officer |
SELL | 12.41K | $124.72K | Direct |
| Jul 10, 26 | KIRN DAVID Chief Executive Officer |
SELL | 58.33K | $737.41K | Direct |
| Jun 30, 26 | BIZILY SCOTT Officer |
SELL | 6.57K | $91.92K | Direct |
| Jun 30, 26 | BIZILY SCOTT Officer |
CONVERSION | 6.57K | $40.70K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BIZILY SCOTT |
Officer | 8.62K | Sale |
GUPTA ASHOO |
Officer | 47.05K | Sale |
KIRN DAVID |
Chief Executive Officer | 767.49K | Sale |
THEUER CHARLES P. |
Director | 41.68K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$693.87M
Enterprise value$371.75M
Revenue (TTM)$92.01M
Gross profit$-145.10M
EBITDA$-188.89M
Net income$-179.18M
EPS (TTM)$-2.63
Free cash flow$-90.77M
Total cash$361.33M
Total debt$39.22M
Book value / share$7.38
Shares outstanding55.24M
Float42.49M
Short % of float24.92%
Dividend yield0.00%
Beta (5Y)2.74
Valuation & profitability ratios
Trailing P/E—
Forward P/E-3.07
PEG ratio—
Price / sales—
Price / book1.70
EV / revenue4.04
EV / EBITDA-1.97
Gross margin-157.70%
Operating margin-2037.16%
Profit margin-194.74%
Return on equity-43.25%
Return on assets-25.09%
Debt / equity9.62
Current ratio8.03
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $85.21M | $37.00K | $20.72M | $3.13M | +230,194.6% |
| Operating revenue | $85.21M | $37.00K | $20.72M | $3.13M | +230,194.6% |
| Research & development | $195.70M | $141.30M | $97.10M | $80.25M | +38.5% |
| Selling, general & admin | $49.06M | $46.58M | $36.49M | $32.91M | +5.3% |
| Total operating expense | $244.76M | $187.88M | $133.59M | $113.16M | +30.3% |
| Operating income | -$159.55M | -$187.84M | -$112.87M | -$110.03M | +15.1% |
| Net interest income | $19.48M | $27.05M | $12.21M | $2.57M | -28.0% |
| Pre-tax income | -$140.11M | -$160.87M | -$100.84M | -$107.49M | +12.9% |
| Net income | -$140.11M | -$160.87M | -$100.84M | -$107.49M | +12.9% |
| Net income to common | -$140.11M | -$160.87M | -$100.84M | -$107.49M | +12.9% |
| Basic EPS | -2.42 | -2.98 | -2.58 | -3.32 | +18.8% |
| Diluted EPS | -2.42 | -2.98 | -2.58 | -3.32 | +18.8% |
| EBIT | -$159.55M | -$187.84M | -$112.87M | -$110.03M | +15.1% |
| EBITDA | -$151.92M | -$181.14M | -$107.12M | -$106.15M | +16.1% |
| Basic shares | 57.93M | 53.94M | 39.13M | 32.35M | +7.4% |
| Diluted shares | 57.93M | 53.94M | 39.13M | 32.35M | +7.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $60.24M | $149.34M | $249.11M | $52.35M | — | -59.7% |
| Cash & short-term investments | $402.65M | $424.88M | $288.23M | $213.55M | — | -5.2% |
| Accounts receivable | — | — | — | $0 | $47.00K | — |
| Total current assets | $413.13M | $434.93M | $296.59M | $220.51M | — | -5.0% |
| Property, plant & equipment | $33.01M | $40.61M | $31.66M | $35.35M | — | -18.7% |
| Total assets | $566.71M | $560.38M | $339.89M | $261.85M | — | +1.1% |
| Total current liabilities | $43.98M | $29.15M | $18.95M | $15.73M | — | +50.9% |
| Total debt | $21.41M | $24.61M | $14.67M | $16.12M | — | -13.0% |
| Total liabilities | $61.05M | $49.78M | $32.06M | $30.51M | — | +22.6% |
| Retained earnings | -$716.30M | -$576.20M | -$415.33M | -$314.49M | — | -24.3% |
| Shareholder equity | $505.66M | $510.61M | $307.83M | $231.34M | — | -1.0% |
| Working capital | $369.15M | $405.78M | $277.64M | $204.78M | — | -9.0% |
| Net tangible assets | $505.66M | $510.61M | $307.83M | $231.34M | — | -1.0% |
| Shares issued | 57.61M | 45.79M | 43.08M | 32.63M | — | +25.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$140.11M | -$160.87M | -$100.84M | -$107.49M | +12.9% |
| Depreciation & amortisation | $7.63M | $6.71M | $5.75M | $3.88M | +13.7% |
| Stock-based compensation | $22.02M | $26.12M | $19.66M | $17.12M | -15.7% |
| Change in working capital | $6.17M | $537.00K | $630.00K | -$1.34M | +1,049.3% |
| Operating cash flow | -$109.08M | -$134.59M | -$75.79M | -$86.69M | +18.9% |
| Capital expenditure | -$536.00K | -$3.79M | -$2.77M | -$11.54M | +85.8% |
| Investing cash flow | -$92.97M | -$302.44M | $115.72M | -$17.05M | +69.3% |
| Financing cash flow | $112.96M | $337.25M | $156.83M | $3.08M | -66.5% |
| Free cash flow | -$109.62M | -$138.37M | -$78.56M | -$98.22M | +20.8% |
| End cash position | $60.24M | $149.34M | $249.11M | $52.35M | -59.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $3.78M | $3.05M | $85.09M | $90.00K | $15.00K | — | +24.1% |
| Operating revenue | $3.78M | $3.05M | $85.09M | $90.00K | $15.00K | — | +24.1% |
| Research & development | $68.28M | $64.98M | $57.61M | $49.44M | $47.95M | — | +5.1% |
| Selling, general & admin | $12.52M | $11.69M | $12.77M | $11.84M | $11.52M | — | +7.2% |
| Total operating expense | $80.81M | $76.67M | $70.38M | $61.27M | $59.47M | — | +5.4% |
| Operating income | -$77.03M | -$73.62M | $14.71M | -$61.19M | -$59.46M | — | -4.6% |
| Net interest income | $4.25M | $4.86M | $4.70M | $4.33M | $4.86M | — | -12.5% |
| Pre-tax income | -$72.94M | -$68.76M | $19.40M | -$56.88M | -$54.66M | — | -6.1% |
| Net income | -$72.94M | -$68.76M | $19.40M | -$56.88M | -$54.66M | — | -6.1% |
| Net income to common | -$72.94M | -$68.76M | $19.40M | -$56.88M | -$54.66M | — | -6.1% |
| Basic EPS | -1.04 | -1.01 | — | -1.01 | -0.98 | -0.86 | -3.0% |
| Diluted EPS | -1.04 | -1.01 | — | -1.01 | -0.98 | -0.86 | -3.0% |
| EBIT | -$77.03M | -$73.62M | $14.71M | -$61.19M | -$59.46M | — | -4.6% |
| EBITDA | -$74.94M | -$71.56M | $16.70M | -$59.18M | -$57.57M | — | -4.7% |
| Basic shares | 70.27M | 68.06M | — | 56.13M | 55.93M | 55.74M | +3.2% |
| Diluted shares | 70.27M | 68.06M | — | 56.13M | 55.93M | 55.74M | +3.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $70.37M | $72.49M | $60.24M | $48.55M | $77.16M | -2.9% |
| Cash & short-term investments | $361.33M | $390.89M | $402.65M | $305.06M | $293.23M | -7.6% |
| Total current assets | $382.96M | $405.36M | $413.13M | $312.38M | $303.29M | -5.5% |
| Property, plant & equipment | $28.93M | $30.94M | $33.01M | $35.06M | $37.15M | -6.5% |
| Total assets | $492.62M | $512.90M | $566.71M | $423.98M | $473.64M | -4.0% |
| Total current liabilities | $47.67M | $43.40M | $43.98M | $37.11M | $34.68M | +9.8% |
| Long-term debt | $19.59M | — | — | — | — | — |
| Total debt | $39.22M | $20.54M | $21.41M | $22.26M | $23.08M | +91.0% |
| Total liabilities | $84.96M | $61.07M | $61.05M | $55.00M | $52.75M | +39.1% |
| Retained earnings | -$858.00M | -$785.06M | -$716.30M | -$735.70M | -$678.83M | -9.3% |
| Shareholder equity | $407.66M | $451.84M | $505.66M | $368.98M | $420.89M | -9.8% |
| Working capital | $335.28M | $361.96M | $369.15M | $275.27M | $268.61M | -7.4% |
| Net tangible assets | $407.66M | $451.84M | $505.66M | $368.98M | $420.89M | -9.8% |
| Shares issued | 55.21M | 52.27M | 57.61M | 46.77M | 46.70M | +5.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$72.94M | -$68.76M | $19.40M | -$56.88M | -$54.66M | — | -6.1% |
| Depreciation & amortisation | $2.09M | $2.06M | $1.98M | $2.00M | $1.89M | — | +1.7% |
| Stock-based compensation | $5.88M | $4.45M | $5.55M | $4.52M | $4.96M | — | +32.1% |
| Change in working capital | -$4.10M | -$4.75M | $2.75M | $5.00M | $5.59M | — | +13.6% |
| Operating cash flow | -$70.00M | -$68.13M | $28.55M | -$46.50M | -$43.38M | — | -2.8% |
| Capital expenditure | — | — | — | — | -$66.00K | -$631.00K | — |
| Investing cash flow | $25.54M | $68.89M | -$128.85M | $17.78M | -$13.85M | — | -62.9% |
| Financing cash flow | $42.34M | $11.48M | $111.98M | $116.00K | $862.00K | — | +268.7% |
| Free cash flow | -$70.05M | -$68.13M | $28.62M | -$46.41M | -$43.44M | — | -2.8% |
| End cash position | $70.37M | $72.49M | $60.24M | $48.55M | $77.16M | — | -2.9% |
Options analytics
Put / call volume
0.32
Call-heavy session
Put / call open interest
2.00
Positioning, not flow
Max pain
6.00
-52.2% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
114
Contracts, this expiry
Put volume
36
Contracts, this expiry
Heaviest call OI
2.00
1 contracts
Heaviest put OI
6.00
4 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.02 | -1.04 | -2.3% |
| Mar 2026 | -1.00 | -1.01 | -1.5% |
| Dec 2025 | -0.53 | 0.43 | +181.4% |
| Sep 2025 | -0.98 | -1.01 | -2.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.05 | 11 | $3.10M | +3,341.8% |
| Next quarter | -1.06 | 11 | $3.87M | -95.4% |
| Current year | -4.15 | 11 | $13.26M | -84.4% |
| Next year | -4.09 | 10 | $20.63M | +55.7% |
Analyst targets & ownership
Mean target$28.09
High target$37.00
Low target$18.00
Implied upside124.73%
Analyst count11
ConsensusSTRONG BUY
Strong buy / Buy2 / 9
Hold1
Sell / Strong sell0 / 0
Held by insiders2.93%
Held by institutions106.04%
Institutions holding219
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
14.05
-11.05% from price
SMA 20
14.18
-11.41% from price
SMA 50
13.51
-7.02% from price
SMA 100
11.95
+4.61% from price
SMA 200
10.47
+20.00% from price
EMA 12
13.88
-9.97% from price
EMA 26
14.02
-10.85% from price
EMA 50
13.53
-7.64% from price
RSI (14)
35.9
Neutral
MACD (12,26,9)
-0.14
Hist -0.29
ATR (14)
0.98
7.81% of price
Realised vol 30D
48.9%
Annualised
Bollinger upper
15.81
20, 2σ
Bollinger lower
12.54
20, 2σ
50 / 200 cross
Golden
13.51 vs 10.47
Trend bias
Above 200
+20.00%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.89
More volatile than market
Correlation to SPY
0.31
Loosely linked
Realised vol 30D
48.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-41.4%
Peak to trough
Max drawdown 5Y
-93.0%
Peak to trough
ATR 14
0.98
7.81% of price
Beta (reported)
2.74
5Y monthly, from filing
Short interest
Shares short
12.01M
Prior 12.29M
Change vs prior
-2.3%
Shorts covering
% of float
24.92%
Heavily shorted
% of shares out
21.74%
Against total outstanding
Days to cover
10.9
Crowded exit
Float
42.49M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 6, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Sep 29, 26 | B of A Securities | MAINTAINED | Buy | Buy |
| Sep 14, 26 | Cantor Fitzgerald | UPGRADE | Neutral | Overweight |
| Jul 31, 26 | B. Riley Securities | INITIATED | — | Buy |
| Jul 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 20, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 19, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Mar 19, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Jan 28, 26 | Barclays | INITIATED | — | Overweight |
| Dec 18, 25 | Chardan Capital | MAINTAINED | Buy | Buy |
| Nov 11, 25 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Nov 11, 25 | Barclays | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-28
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-07-20
Corporate Changes & Voting Matters
8-K · 2026-06-29
Corporate Changes & Voting Matters
8-K · 2026-06-22
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-05-11
Periodic Financial Reports
10-Q · 2026-05-07
Annual Report to Shareholders
ARS · 2026-04-28
Headlines
4DMT to Host Investor Day on October 21, 2026
GlobeNewswire · 2d ago
This is the top biotech stock pick from B Riley Securities
Investing.com · 7d ago
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
Stocktwits · 8d ago
4D Molecular Therapeutics Begins Phase 3 Trial of 4D-150 in Diabetic Macular Edema
MT Newswires · 9d ago
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
GlobeNewswire · 9d ago
4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing
MT Newswires · 20d ago
Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight From Neutral
MT Newswires · 23d ago
4DMT Announces New Employment Inducement Grants
GlobeNewswire · 25d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.